The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...

The drug is groundbreaking, potentially eliminating the need for a long-sought-after HIV vaccine. In her own words: Anne ...

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...

The US Food and Drug Administration (FDA) has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a ...

Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

General, Winnie Byanyima, has called for a drastic and transparent reduction in the cost of lenacapavir, a twice-yearly ...

Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.

WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global ...

Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...

Gilead Sciences, Inc. GILD obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the ...